Launch One Acquisition Corp. Announces Business Combination Deal with Minovia Therapeutics.

Launch One Acquisition Corp. has entered a business combination deal with Minovia Therapeutics. The blank check company has not selected a target and has not initiated any substantive discussions. The deal aims to effect a merger, amalgamation, or similar business combination with one or more businesses. The company has no operations or revenues.

Launch One Acquisition Corp. (LPAA), a special purpose acquisition company focused on healthcare innovation, has entered into a definitive business combination agreement with Minovia Therapeutics Ltd. (Minovia). The proposed business combination aims to create a publicly traded, clinical-stage biotechnology company focused on developing and commercializing Mitochondrial Augmentation Technology (MAT) [1].

The business combination will result in the formation of a new entity, Mito US One Ltd., which is expected to be listed on Nasdaq. The deal assigns Minovia a pre-money equity valuation of $180 million, which will be increased by additional proceeds from a bridge financing of at least $5 million. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions and shareholder approvals [1].

Minovia is a clinical-stage biotechnology company developing first-in-class therapies to treat mitochondrial diseases and combat age-related decline. Its lead product, MNV-201, is currently being tested in clinical trials for Pearson Syndrome and Myelodysplastic Syndrome. Minovia has treated 23 patients with various mitochondrial conditions, demonstrating significant clinical outcomes with no drug-related adverse responses [1].

Launch One's trust account holds approximately $239.7 million in cash, a portion of which may be available to the combined company following the transaction. The deal is expected to provide Minovia with additional capital to facilitate accelerating its growth and development pipeline, including reaching clinical and regulatory milestones, technology transfer, and the eventual commercial launch of its longevity-focused offerings [1].

The business combination positions Minovia as a first mover in advanced mitochondrial medicine, with a robust pipeline and a clear path to pivotal trials. The company plans to launch MAT-based offerings through global longevity clinic partnerships beginning in 2026. Minovia believes its accumulated clinical data and preclinical results support its regulatory strategy across multiple indications [1].

The boards of directors of both Minovia and Launch One have unanimously approved the transaction. Additional information about the transaction will be provided in a Current Report on Form 8-K to be filed with the Securities and Exchange Commission (SEC) and will be available at www.sec.gov. Launch One and Minovia intend to file relevant materials with the SEC, including a registration statement on Form F-4 [1].

References:
[1] https://www.globenewswire.com/news-release/2025/06/25/3105093/0/en/Minovia-Therapeutics-Ltd-and-Launch-One-Acquisition-Corp-Announce-Proposed-Business-Combination-to-Create-Nasdaq-Listed-Mitochondrial-Therapy-Company-in-1-Trillion-Mitochondrial-an.html